vs

Side-by-side financial comparison of enCore Energy Corp. (EU) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.

Silence Therapeutics plc is the larger business by last-quarter revenue ($15.7M vs $12.4M, roughly 1.3× enCore Energy Corp.). Silence Therapeutics plc runs the higher net margin — -14.7% vs -173.9%, a 159.2% gap on every dollar of revenue.

Devon Energy Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware with operational headquarters in the 50-story Devon Energy Center in Oklahoma City, Oklahoma. Its operations are in the Delaware Basin, Eagle Ford Group, and the Rocky Mountains.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

EU vs SLN — Head-to-Head

Bigger by revenue
SLN
SLN
1.3× larger
SLN
$15.7M
$12.4M
EU
Higher net margin
SLN
SLN
159.2% more per $
SLN
-14.7%
-173.9%
EU

Income Statement — Q4 FY2025 vs Q1 FY2024

Metric
EU
EU
SLN
SLN
Revenue
$12.4M
$15.7M
Net Profit
$-21.5M
$-2.3M
Gross Margin
37.9%
82.2%
Operating Margin
-135.9%
-35.6%
Net Margin
-173.9%
-14.7%
Revenue YoY
Net Profit YoY
EPS (diluted)
$-0.11
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EU
EU
SLN
SLN
Q4 25
$12.4M
Q3 25
$8.9M
Q2 25
$3.7M
Q1 25
$18.2M
Q1 24
$15.7M
Net Profit
EU
EU
SLN
SLN
Q4 25
$-21.5M
Q3 25
$-4.8M
Q2 25
$-6.3M
Q1 25
$-24.2M
Q1 24
$-2.3M
Gross Margin
EU
EU
SLN
SLN
Q4 25
37.9%
Q3 25
43.8%
Q2 25
30.8%
Q1 25
-0.1%
Q1 24
82.2%
Operating Margin
EU
EU
SLN
SLN
Q4 25
-135.9%
Q3 25
-158.2%
Q2 25
-526.1%
Q1 25
-85.7%
Q1 24
-35.6%
Net Margin
EU
EU
SLN
SLN
Q4 25
-173.9%
Q3 25
-53.7%
Q2 25
-172.7%
Q1 25
-132.9%
Q1 24
-14.7%
EPS (diluted)
EU
EU
SLN
SLN
Q4 25
$-0.11
Q3 25
$-0.03
Q2 25
$-0.03
Q1 25
$-0.13
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EU
EU
SLN
SLN
Cash + ST InvestmentsLiquidity on hand
$52.4M
Total DebtLower is stronger
$110.0M
Stockholders' EquityBook value
$229.2M
$156.8M
Total Assets
$430.4M
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EU
EU
SLN
SLN
Q4 25
$52.4M
Q3 25
$91.9M
Q2 25
$26.9M
Q1 25
$29.7M
Q1 24
Total Debt
EU
EU
SLN
SLN
Q4 25
$110.0M
Q3 25
$109.3M
Q2 25
Q1 25
Q1 24
Stockholders' Equity
EU
EU
SLN
SLN
Q4 25
$229.2M
Q3 25
$248.6M
Q2 25
$264.7M
Q1 25
$267.9M
Q1 24
$156.8M
Total Assets
EU
EU
SLN
SLN
Q4 25
$430.4M
Q3 25
$441.9M
Q2 25
$359.4M
Q1 25
$362.6M
Q1 24
Debt / Equity
EU
EU
SLN
SLN
Q4 25
0.48×
Q3 25
0.44×
Q2 25
Q1 25
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EU
EU
SLN
SLN
Operating Cash FlowLast quarter
$12.9M
$-9.1M
Free Cash FlowOCF − Capex
$7.2M
FCF MarginFCF / Revenue
57.8%
Capex IntensityCapex / Revenue
46.7%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-45.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EU
EU
SLN
SLN
Q4 25
$12.9M
Q3 25
$-20.3M
Q2 25
$-9.9M
Q1 25
$-7.7M
Q1 24
$-9.1M
Free Cash Flow
EU
EU
SLN
SLN
Q4 25
$7.2M
Q3 25
$-26.3M
Q2 25
$-14.1M
Q1 25
$-11.7M
Q1 24
FCF Margin
EU
EU
SLN
SLN
Q4 25
57.8%
Q3 25
-296.6%
Q2 25
-385.2%
Q1 25
-64.1%
Q1 24
Capex Intensity
EU
EU
SLN
SLN
Q4 25
46.7%
Q3 25
68.0%
Q2 25
115.1%
Q1 25
21.7%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons